한빛사논문
Minsuk Kong 1,2,6, Domenico D’Atri 1,6, Maria Teresa Bilotta 1, Bailey Johnson 3, Taylor B. Updegrove 1, Devorah L. Gallardo 4, Federico Machinandiarena 1, I-Lin Wu 1, Maira Alves Constantino 3, Stephen M. Hewitt 5, Kandice Tanner 3, David J. Fitzgerald 1, Kumaran S. Ramamurthi 1,7
1Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
2Department of Food Science and Technology, Seoul National University of Science and Technology, Seoul 01811, South Korea
3Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
4Laboratory Animal Sciences Program, Leidos Biomedical Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
5Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
6These authors contributed equally
7Lead contact
Corresponding authors: Kandice Tanner, David J. Fitzgerald, Kumaran S. Ramamurthi
Abstract
Delivery of cancer therapeutics to non-specific sites decreases treatment efficacy while increasing toxicity. In ovarian cancer, overexpression of the cell surface marker HER2, which several therapeutics target, relates to poor prognosis. We recently reported the assembly of biocompatible bacterial spore-like particles, termed "SSHELs." Here, we modify SSHELs with an affibody directed against HER2 and load them with the chemotherapeutic agent doxorubicin. Drug-loaded SSHELs reduce tumor growth and increase survival with lower toxicity in a mouse tumor xenograft model compared with free drug and with liposomal doxorubicin by preferentially accumulating in the tumor mass. Target cells actively internalize and then traffic bound SSHELs to acidic compartments, whereupon the cargo is released to the cytosol in a pH-dependent manner. We propose that SSHELs represent a versatile strategy for targeted drug delivery, especially in cancer settings.
논문정보
관련 링크
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기